{
    "clinical_study": {
        "@rank": "121248", 
        "brief_summary": {
            "textblock": "RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing\n      so they stop growing or die.\n\n      PURPOSE: Phase II trial to study the effectiveness of topotecan in treating patients with\n      recurrent brain tumor."
        }, 
        "brief_title": "Topotecan in Treating Patients With Recurrent Brain Tumors", 
        "completion_date": "December 2009", 
        "condition": "Brain and Central Nervous System Tumors", 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Nervous System Neoplasms", 
                "Oligodendroglioma", 
                "Central Nervous System Neoplasms", 
                "Astrocytoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES: I. Determine the efficacy of topotecan in patients with recurrent anaplastic\n      oligodendroglioma or anaplastic mixed oligoastrocytoma. II. Determine the qualitative and\n      quantitative toxicity of topotecan in this patient population on this schedule.\n\n      OUTLINE: This is a multicenter study. Patients receive intravenous topotecan over 30 minutes\n      daily for 5 days every 3 weeks. Treatment continues in the absence of disease progression or\n      unacceptable toxicity. Patients will be followed every 3 months until death.\n\n      PROJECTED ACCRUAL: Up to 30 evaluable patients will be accrued within 2-3 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS: Histologically proven recurrent anaplastic oligodendroglioma or\n        anaplastic mixed oligoastrocytoma following primary surgery and radiation therapy Tumors\n        for anaplastic mixed oligoastrocytoma must contain at least 25% oligodendroglial elements\n        Tumors must be clinically aggressive for patients with only 1 anaplastic feature Prior low\n        grade oligodendrogliomas or oligoastrocytomas undergoing repeat biopsy following clinical\n        or radiological progression are eligible Bidimensionally measurable and progressive\n        lesions by CT or MRI\n\n        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-3 Life expectancy:\n        Not specified Hematopoietic: Absolute granulocyte count at least 1,500/mm3 Platelet count\n        at least 100,000/mm3 Hepatic: Not specified Renal: Creatinine normal Other: Not pregnant\n        or nursing Fertile patients must use effective contraception No prior malignancies except\n        curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer No other\n        serious illness or medical condition No active uncontrolled infection No history of\n        neurologic or psychiatric disorder\n\n        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks\n        since chemotherapy No more than 1 prior chemotherapy regimen No prior camptothecin\n        derivatives Endocrine therapy: At least 2 weeks on stable steroid therapy, if necessary\n        Radiotherapy: At least 2 months since prior radiotherapy No prior radiation therapy for\n        recurrent disease Surgery: At least 6 weeks since prior surgery (except biopsy only) Prior\n        surgery for recurrent disease allowed (including stereotactic biopsy or partial resection)\n        Other: No concurrent experimental drugs or anticancer therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 1, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00003372", 
            "org_study_id": "I109", 
            "secondary_id": [
                "CAN-NCIC-IND109", 
                "CDR0000066362"
            ]
        }, 
        "intervention": {
            "intervention_name": "topotecan hydrochloride", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Topotecan"
        }, 
        "keyword": [
            "recurrent adult brain tumor", 
            "adult anaplastic oligodendroglioma", 
            "adult mixed glioma"
        ], 
        "lastchanged_date": "November 7, 2010", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CAN-NCIC-IND109"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 4N2"
                    }, 
                    "name": "Tom Baker Cancer Center - Calgary"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 1Z2"
                    }, 
                    "name": "Cross Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 4E6"
                    }, 
                    "name": "BC Cancer Agency"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winnipeg", 
                        "country": "Canada", 
                        "state": "Manitoba", 
                        "zip": "R3E 0V9"
                    }, 
                    "name": "CancerCare Manitoba"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kingston", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K7L 5P9"
                    }, 
                    "name": "Kingston Regional Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "Cancer Care Ontario-London Regional Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1Y 4K7"
                    }, 
                    "name": "Ottawa Regional Cancer Centre - Civic Campus"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "Princess Margaret Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M4N 3M5"
                    }, 
                    "name": "Toronto Sunnybrook Regional Cancer Centre"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2L-4M1"
                    }, 
                    "name": "Centre Hospitalier de l'Universite de Montreal"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2W 1S6"
                    }, 
                    "name": "McGill University Department of Oncology"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "official_title": "A Phase II Study of Topotecan in Patients With Anaplastic Oligodendroglioma or Anaplastic Mixed Oligoastrocytoma", 
        "overall_official": {
            "affiliation": "CHUM - Hotel Dieu Hospital", 
            "last_name": "Karl Belanger, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00003372"
        }, 
        "results_reference": {
            "PMID": "14586216", 
            "citation": "Belanger K, MacDonald D, Cairncross G, Gertler S, Forsyth P, Burdette-Radoux S, Bergeron J, Soulieres D, Ludwin S, Wainman N, Eisenhauer E. A phase II study of topotecan in patients with anaplastic oligodendroglioma or anaplastic mixed oligoastrocytoma. Invest New Drugs. 2003 Nov;21(4):473-80."
        }, 
        "source": "NCIC Clinical Trials Group", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NCIC Clinical Trials Group", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 1997", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2010"
    }, 
    "geocoordinates": {
        "BC Cancer Agency": "49.261 -123.114", 
        "Cancer Care Ontario-London Regional Cancer Centre": "42.979 -81.246", 
        "CancerCare Manitoba": "49.9 -97.137", 
        "Centre Hospitalier de l'Universite de Montreal": "45.509 -73.554", 
        "Cross Cancer Institute": "53.544 -113.49", 
        "Kingston Regional Cancer Centre": "44.231 -76.486", 
        "McGill University Department of Oncology": "45.509 -73.554", 
        "Ottawa Regional Cancer Centre - Civic Campus": "45.422 -75.697", 
        "Princess Margaret Hospital": "43.653 -79.383", 
        "Tom Baker Cancer Center - Calgary": "51.045 -114.057", 
        "Toronto Sunnybrook Regional Cancer Centre": "43.653 -79.383"
    }
}